Metraipolis › archive › dc_cf142b34d929
EpCAM-targeted near-infrared photoimmunotherapy (NIR-PIT) for the treatment of breast cancer — Europe PMC PMID:40792441
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40792441
- DOI
- 10.1080/07853890.2025.2540599
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-08T02:30:27.465Z
- SHA-256 of the archived text
b53034fe2de2f3a8c862d1ba128089c476a03d23e950abe4c1c72051fe9ad629- Stable URL of this page
https://metraipolis.com/documento/dc_cf142b34d929
How to cite
EpCAM-targeted near-infrared photoimmunotherapy (NIR-PIT) for the treatment of breast cancer — Europe PMC PMID:40792441 — Europe PMC (en), https://europepmc.org/article/MED/40792441 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_cf142b34d929 (Metraipolis archive dc_cf142b34d929, sha256 b53034fe2de2f3a8c862d1ba128089c476a03d23e950abe4c1c72051fe9ad629)
BibTeX
@misc{dccf142b34d929,
title = {EpCAM-targeted near-infrared photoimmunotherapy (NIR-PIT) for the treatment of breast cancer — Europe PMC PMID:40792441},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40792441},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_cf142b34d929; sha256 b53034fe2de2f3a8c862d1ba128089c476a03d23e950abe4c1c72051fe9ad629},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/40792441. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Background: Near-infrared photoimmunotherapy (NIR-PIT) is a targeted cancer treatment that uses antibody-IR700 conjugates and selectively destroys cancer cells expressing a target antigen when exposed to near-infrared (NIR) light. NIR-PIT not only destroys targeted cancer cells but also induces anticancer immune activation. Currently, epidermal growth factor receptor (EGFR) is the only clinically approved target for NIR-PIT. To expand the therapeutic potential of this therapy, we investigated EpCAM as a potential target for NIR-PIT. Method: We first evaluated the target cell-killing efficacy of EpCAM-targeted NIR-PIT (EpCAM-NIR-PIT) using the antibody Edrecolomab in human breast and colon cancer models characterized by high EpCAM expression. Next, we evaluated anticancer immune activity induced by EpCAM-NIR-PIT with an anti-PD-1 immune checkpoint inhibitor in a mouse breast cancer model in immunocompetent mice. Result: Both in vitro and in vivo studies demonstrated effective cell killing in response to EpCAM-NIR-PIT using Edrecolomab. In vivo EpCAM-NIR-PIT in a breast cancer model in immunodeficient mice demonstrated an initial reduction in tumour size followed by delayed regrowth relative to controls. The analysis of immune cells revealed that this combination therapy led to robust activation of CD8+ T cells and their differentiation into effector cells, resulting in significant tumour suppression with a 50% complete remission (CR) rate. Furthermore, mice that achieved CR demonstrated resistance to tumour rechallenge, indicating the establishment of long-term anticancer immunity. Conclusion: This study demonstrated that EpCAM-NIR-PIT, particularly when combined with immune-activating agents such as anti-PD-1, is a promising new approach for cancer treatment, inducing durable and systemic anticancer immunity. Tema degli esploratori: ricerca e scienza aperta (ricerca Europe PMC «preprint», solo open access). Pubblicazione: Annals of medicine, 2025 (prima pubblicazione 2025-08-12). Identificativi: PMID 40792441 · PMCID PMC12344674 · DOI 10.1080/07853890.2025.2540599. Parole chiave degli autori: Cancer; Breast cancer; Epcam; Near-infrared Photoimmunotherapy; Nir-pit. Descrittori MeSH principali: Breast Neoplasms; Immunotherapy; Phototherapy; Epithelial Cell Adhesion Molecule. Pagina: https://europepmc.org/article/MED/40792441 — https://doi.org/10.1080/07853890.2025.2540599. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-08T01:51:01.626Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.